What immune checkpoint inhibitor is best for survival in metastatic cervical cancer?
For metastatic cervical cancer, several immune checkpoint inhibitors (ICIs) have been studied, but pembrolizumab (Keytruda) has the strongest evidence for improving survival. A network meta-analysis ranked pembrolizumab highest for overall survival among ICIs 3. The KEYNOTE-826 trial showed that adding pembrolizumab to chemotherapy significantly extended life, with median overall survival of 28.6 months in PD-L1 positive patients versus 16.5 months with chemotherapy alone 45. Other ICIs like atezolizumab have been studied but with less robust survival data 1.
What the research says
A 2025 network meta-analysis compared all available ICIs for cervical cancer and found that pembrolizumab plus standard therapy had the highest probability of being the best for overall survival 3. This analysis included phase 3 trials and used SUCRA rankings to compare treatments indirectly 3. The KEYNOTE-826 trial, a phase 3 study, confirmed that pembrolizumab combined with platinum-based chemotherapy (with or without bevacizumab) improved overall survival in patients with PD-L1 positive tumors (CPS ≥1) and in the overall population 45. At final analysis with 39 months follow-up, median overall survival was 28.6 months with pembrolizumab versus 16.5 months with placebo in PD-L1 CPS ≥1 patients (HR 0.60) 5. For all-comers, median survival was 26.4 vs 16.8 months (HR 0.63) 5. Another ICI, atezolizumab, has been studied in combination with SBRT in a phase 2 trial, but that trial focused on response rate rather than survival, and the median duration of response was 8.6 months 1. The evidence for pembrolizumab is stronger because it comes from large randomized trials with survival endpoints 45. A retrospective study also noted that the combined neutrophil-to-lymphocyte ratio (NLR) can help predict progression-free survival in patients receiving ICIs, including pembrolizumab, which may help guide treatment decisions 2.
What to ask your doctor
- Is pembrolizumab an option for my type of metastatic cervical cancer, and do I need PD-L1 testing?
- What are the expected benefits of adding pembrolizumab to chemotherapy based on my PD-L1 status?
- What side effects should I watch for with pembrolizumab, and how are they managed?
- Are there other immune checkpoint inhibitors available if I cannot take pembrolizumab?
- How does the combined neutrophil-to-lymphocyte ratio (NLR) affect my prognosis with immunotherapy?
This question is drawn from common patient questions about Allergy & Immunology and answered using cited medical research. We do not provide individualized advice.